Drug intelligence / Profile preview

XPC-418

Development stage: Preclinical
Lead developer: Xenon Pharmaceuticals
Modality: Small Molecules

Overview

XPC-418 is a small molecule drug candidate described as a Nav1.1 potentiator. In preclinical studies, XPC-418 was shown to alter brain activity in Scn1a+/- mice, making their phenotype more similar to that of wild-type animals. This suggests its mechanism involves enhancing the function of the sodium channel protein type 1 subunit alpha (Nav1.1), which may have implications for neurological disorders characterized by Nav1.1 dysfunction[1][4]. The developer associated with this compound is Xenon Pharmaceuticals.

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on XPC-418.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XPC-418.

Explore the full profile